Bergen, Norway, February 21st, 2024: Lifecare AS (LIFE), a clinical stage
medical sensor company developing the next generation Continuous Glucose
Monitor (CGM), announces today that the Board of Directors has decided to
prepare for submitting application for listing of Lifecare's shares at the
main list of Oslo Stock Exchange (OSE), transferring from the current listing
on Euronext Growth.
- Stepping up to the major league at OSE is an important decision for
Lifecare. We are comfortable with our organization's capability to adhere to
the strict requirements and obligations connected with being listed at OSE,
says CEO Joacim Holter at Lifecare.
Lifecare has been through a year with several milestone achievements when it
comes to proof of concept of our cutting edge Sencell sensor. The company's
CGM technology has proven its competitive properties in terms of accuracy,
robustness, and longevity.
- We are now really on the brink of automated pilot production, and we see a
new era for our sensor technology. We expect that a listing on the main list
at Oslo Stock Exchange will further accelerate the overall growth of our
company, attract, and secure a more flexible and even broader investor base
that will support Lifecare in reaching our growth targets. We also expect that
an uplisting will increase share liquidity and strengthen the profile of
Lifecare, says Holter.
In accordance with the Board of Directors' decision, Lifecare management will
prepare to submit the application for listing on OSE in the course of Q3 2024.
The Board of Director's outlook for the Lifecare share is to be ready for
trading on Oslo Børs' main list in October 2024, says Joacim Holter.
About us
Lifecare AS is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare's main focus is
to bring the next generation of Continuous Glucose Monitoring ("CGM") systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
("NTR") on the sensor body for read-out of pressure variations. Lifecare's
sensor technology is referred to as "Sencell" and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body.
Contacts
For further information, please contact:
Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40
Asle Wingsternes, Head of Communications & Public Affairs,
asle.wingsternes@lifecare.no, +47 41 61 42 52
This information has been submitted pursuant to the Securities Trading Act §
5-12 and MAR Article 19 no. 3. The information was submitted for publication
at 2024-02-21 08:00 CET.